Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According t...
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing...
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease
- Conditions
- Interventions
- First Posted Date
- 2015-12-14
- Last Posted Date
- 2024-12-10
- Target Recruit Count
- 45
- Registration Number
- NCT02629120
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
- Conditions
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 32
- Registration Number
- NCT02627573
- Locations
- 🇷🇺
First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation
Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2020-01-14
- Target Recruit Count
- 20
- Registration Number
- NCT02605460
- Locations
- 🇲🇽
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT02589145
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 17
- Registration Number
- NCT02582775
- Locations
- 🇺🇸
University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States
Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Nantes University Hospital
- Registration Number
- NCT02577094
VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT02544425
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2024-10-29
- Target Recruit Count
- 23
- Registration Number
- NCT02512497
- Locations
- 🇺🇸
The Ohio State University Cancer Center, Columbus, Ohio, United States
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 83
- Registration Number
- NCT02506959
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- University of Louisville
- Target Recruit Count
- 10
- Registration Number
- NCT02472392
- Locations
- 🇺🇸
University of Louisville, Louisville, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.